Literature DB >> 16783163

'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis.

Yuan Rong1, Donald L Durden, Erwin G Van Meir, Daniel J Brat.   

Abstract

Glioblastoma (GBM) is a highly malignant, rapidly progressive astrocytoma that is distinguished pathologically from lower grade tumors by necrosis and microvascular hyperplasia. Necrotic foci are typically surrounded by "pseudopalisading" cells-a configuration that is relatively unique to malignant gliomas and has long been recognized as an ominous prognostic feature. Precise mechanisms that relate morphology to biologic behavior have not been described. Recent investigations have demonstrated that pseudopalisades are severely hypoxic, overexpress hypoxia-inducible factor (HIF-1), and secrete proangiogenic factors such as VEGF and IL-8. Thus, the microvascular hyperplasia in GBM that provides a new vasculature and promotes peripheral tumor expansion is tightly linked with the emergence of pseudopalisades. Both pathologic observations and experimental evidence have indicated that the development of hypoxia and necrosis within astrocytomas could arise secondary to vaso-occlusion and intravascular thrombosis. This emerging model suggests that pseudopalisades represent a wave of tumor cells actively migrating away from central hypoxia that arises after a vascular insult. Experimental glioma models have shown that endothelial apoptosis, perhaps resulting from angiopoetin-2, initiates vascular pathology, whereas observations in human tumors have clearly demonstrated that intravascular thrombosis develops with high frequency in the transition to GBM. Tissue factor, the main cellular initiator of thrombosis, is dramatically upregulated in response to PTEN loss and hypoxia in human GBM and could promote a prothrombotic environment that precipitates these events. A prothrombotic environment also activates the family of protease activated receptors (PARs) on tumor cells, which are G-protein-coupled and enhance invasive and proangiogenic properties. Vaso-occlusive and prothrombotic mechanisms in GBM could readily explain the presence of pseudopalisading necrosis in tissue sections, the rapid peripheral expansion on neuroimaging, and the dramatic shift to an accelerated rate of clinical progression resulting from hypoxia-induced angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783163     DOI: 10.1097/00005072-200606000-00001

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  193 in total

1.  Calibrating a Predictive Model of Tumor Growth and Angiogenesis with Quantitative MRI.

Authors:  David A Hormuth; Angela M Jarrett; Xinzeng Feng; Thomas E Yankeelov
Journal:  Ann Biomed Eng       Date:  2019-04-08       Impact factor: 3.934

2.  A proteome comparison between physiological angiogenesis and angiogenesis in glioblastoma.

Authors:  Dana A M Mustafa; Lennard J Dekker; Christoph Stingl; Andreas Kremer; Marcel Stoop; Peter A E Sillevis Smitt; Johan M Kros; Theo M Luider
Journal:  Mol Cell Proteomics       Date:  2012-01-25       Impact factor: 5.911

3.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

4.  Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis.

Authors:  Xinhai Yang; Dianhua Qiao; Kristy Meyer; Andreas Friedl
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 5.  Glioblastoma stem cells: Molecular characteristics and therapeutic implications.

Authors:  Nermin Sumru Bayin; Aram Sandaldjian Modrek; Dimitris George Placantonakis
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

6.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

7.  Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.

Authors:  Merryl R Lobo; Sarah C Green; Matthias C Schabel; G Yancey Gillespie; Randall L Woltjer; Martin M Pike
Journal:  Neuro Oncol       Date:  2013-10-03       Impact factor: 12.300

8.  Mutant IDH1 and thrombosis in gliomas.

Authors:  Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2016-09-23       Impact factor: 17.088

9.  The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  J Cell Commun Signal       Date:  2013-03-15       Impact factor: 5.782

10.  EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.

Authors:  Li Li; Amalia Dutra; Evgenia Pak; Joseph E Labrie; Rachel M Gerstein; Pier Paolo Pandolfi; Larry D Recht; Alonzo H Ross
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.